BRCA2 and ovarian serous adenocarcinoma: The first poly(ADP-ribose) polymerase (PARP)-inhibitor (PARPi) received the approval from the European Medicines Agency (EMA) in 2014 for use as a maintenance therapy in relapsed high-grade serous ovarian cancer (HGSOC) patients with platinum-sensitivity and with BRCA1/BRCA2 somatic or germline variants [7,8].